Closing Thoughts on the Current Ovarian Cancer Treatment Landscape
Ronald D. Alvarez, MD, MBA, provides closing commentary on the current ovarian cancer treatment landscape and the promising outlook over the next 20 years.
Read More
Harnessing Biomarkers & Molecular Profiling in Ovarian Cancer Treatment
A medical professional examines the pivotal roles of molecular profiling, next-generation sequencing, and germline testing in guiding treatment decisions for ovarian cancer.
Tailored Therapy: Decision Making for Ovarian Cancer Treatment
A medical expert discusses treatment decision-making and modalities for ovarian cancer, including palliative care and hospice.
MIRASOL trial and DESTINY-PanTumor02 Trial Overview
Ronald D. Alvarez, MD, MBA, gives an analysis of the MIRASOL and DESTINY-PanTumor02 trials, including a comparison of study arms and discussion of HER2/neu targeting.
Exploring Therapies for Platinum Sensitive & Platinum-Resistant Ovarian Cancer
A medical expert discusses efficacy of approaches such as carboplatin doublets, checkpoint inhibitors, and PARP inhibitors for patients with platinum sensitive and platinum-resistant ovarian cancer.
NCCN Guidelines: Implementing New Therapy Options for Ovarian Cancer
Ronald D. Alvarez, MD, MBA, discusses challenges in implementing updated NCCN guidelines, such as coverage limitations imposed by payers.
